Copart stock hits 52-week low at 26.72 USD

Copart shares hit a 52-week low of $26.74, 42% below their 52-week high, after declining nearly 38% over one year. Fiscal Q4 2026 revenue rose 2.4% year over year to $1.152 billion, but gross margin fell to about 42% amid higher facility and vehicle procurement costs, and U.S. insurance volumes declined 7.5%. Copart announced a roughly $1.9 billion acquisition of ACV Auctions for $10.50 per share in cash; analysts were divided, with Barrington upgrading to Outperform at $40, while HSBC downgraded to Hold at $36 and Freedom Broker cut its target to $36 from $39 while retaining Buy.

Analysis

The key issue is not CPRT’s drawdown but whether weakness in its insurance channel is cyclical or a share-loss signal. The reported divergence from RBA is worth monitoring, but insurance-loss volumes and RBA’s auto volumes may reflect different channels and geographies; do not treat them as directly comparable until filings confirm the mix. If CPRT’s insurance volumes remain weak while RBA continues growing in comparable salvage categories, the market may be pricing a structural competitive shift rather than merely slower growth.

Buying ACVA adds a dealer-focused auction channel that could diversify CPRT’s exposure over time, but it does not repair near-term insurance volumes. Integration, purchase-price discipline, and any margin drag matter more over the next 1–3 months than headline strategic fit. The cash offer also caps ACVA’s upside around the deal consideration, subject to the actual trading price and closing conditions; verify terms and approvals before considering an event-driven position.

Over 6–18 months, the thesis turns on whether CPRT can stabilize core volumes while integrating ACVA without compounding facility and procurement cost pressure. The undervaluation claim is not independently established by the supplied figures. A broad-market record high is not a catalyst for CPRT-specific earnings recovery. The bearish case is falsified by sustained insurance-volume stabilization and improving margins; persistent relative volume underperformance or further margin deterioration would strengthen it.

Key Decisions for Investors

• Watch, rather than chase the 52-week-low narrative: require the next CPRT volume and margin update to show stabilization before adding directional exposure. Reassess if insurance volumes remain materially negative or gross margin continues to contract.
• Consider a small, catalyst-driven RBA-over-CPRT relative-value position only after confirming comparable salvage-channel volume data. Exit or avoid it if the apparent divergence is mainly mix/geography or CPRT’s subsequent releases show recovery.
• Treat ACVA as a deal-arbitrage watch, not an automatic long: compare its live price with the $10.50 cash consideration and verify financing, closing conditions, and regulatory status. The spread must compensate for closing and timing risk.
• For CPRT, track acquisition disclosures on integration costs, segment growth, and margin contribution. A credible path to accretion alongside core-volume stabilization could reverse the bearish setup; rising costs without growth would argue against the undervaluation thesis.